AR049113A1 - Un metodo para preparar una solucion oftalmica y solucion oftalmica obtenida de un agente activo como latanoprost - Google Patents
Un metodo para preparar una solucion oftalmica y solucion oftalmica obtenida de un agente activo como latanoprostInfo
- Publication number
- AR049113A1 AR049113A1 ARP050102140A ARP050102140A AR049113A1 AR 049113 A1 AR049113 A1 AR 049113A1 AR P050102140 A ARP050102140 A AR P050102140A AR P050102140 A ARP050102140 A AR P050102140A AR 049113 A1 AR049113 A1 AR 049113A1
- Authority
- AR
- Argentina
- Prior art keywords
- ophthalmic solution
- preparing
- latanoprost
- active agent
- solution obtained
- Prior art date
Links
- 229940054534 ophthalmic solution Drugs 0.000 title abstract 5
- 239000002997 ophthalmic solution Substances 0.000 title abstract 5
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 title abstract 3
- 229960001160 latanoprost Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000013543 active substance Substances 0.000 title abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 229960001342 dinoprost Drugs 0.000 abstract 1
- -1 latanoprost Chemical compound 0.000 abstract 1
- PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Método para preparar una solucion oftálmica y solucion oftálmica obtenida por el método, la cual comprende un agente activo análogo de la prostaglandina F2, tal como latanoprost, y presenta estabilidad química a temperatura ambiente, seguridad, inocuidad y eficacia en el tratamiento del paciente. La nueva solucion oftálmica acuosa se distingue porque su valor farmacéutico radica en el manejo de un vehículo de fácil acceso que no solamente permite la solubilidad del latanoprost sino que también favorece su estabilidad química y una mayor tolerancia del paciente a su aplicacion oftálmica para el tratamiento de glaucoma.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/MX2004/000034 WO2005115401A1 (es) | 2004-05-26 | 2004-05-26 | Un método para preparar una solución oftálmica de latanoprost y solución resultante |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049113A1 true AR049113A1 (es) | 2006-06-28 |
Family
ID=35450648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102140A AR049113A1 (es) | 2004-05-26 | 2005-05-24 | Un metodo para preparar una solucion oftalmica y solucion oftalmica obtenida de un agente activo como latanoprost |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US8293789B2 (es) |
| EP (1) | EP1759702B1 (es) |
| AR (1) | AR049113A1 (es) |
| AT (1) | ATE419854T1 (es) |
| BR (1) | BRPI0418866A (es) |
| DE (1) | DE602004018990D1 (es) |
| DK (1) | DK1759702T3 (es) |
| ES (1) | ES2320770T3 (es) |
| PL (1) | PL1759702T3 (es) |
| PT (1) | PT1759702E (es) |
| SI (1) | SI1759702T1 (es) |
| WO (1) | WO2005115401A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9579341B2 (en) | 2007-05-16 | 2017-02-28 | Johnson & Johnson Consumer Inc. | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
| US8609634B2 (en) * | 2007-05-16 | 2013-12-17 | Mcneil-Ppc, Inc. | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
| WO2009007828A1 (en) * | 2007-07-11 | 2009-01-15 | Ophthalmopharma Ag | Complexes of prostaglandin derivatives and monosubstituted, charged beta-cyclodextrins |
| JP5668476B2 (ja) * | 2007-10-08 | 2015-02-12 | オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物 |
| US8455547B2 (en) * | 2008-02-05 | 2013-06-04 | Allergan, Inc. | Substituted cyclopentanes having prostaglandin activity |
| ITRM20080182A1 (it) * | 2008-04-07 | 2009-10-08 | Medivis S R L | Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma. |
| US9481856B2 (en) * | 2008-06-09 | 2016-11-01 | Bausch & Lomb Incorporated | Pharmaceutical formulations comprising stabilized polysaccharides and source of hydrogen peroxide |
| US10463677B2 (en) * | 2008-11-07 | 2019-11-05 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
| WO2010089355A1 (en) * | 2009-02-04 | 2010-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
| DE102009021372A1 (de) * | 2009-05-14 | 2010-11-18 | Ursapharm Arzneimittel Gmbh | Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung |
| CN102458370A (zh) * | 2009-06-09 | 2012-05-16 | 卢克斯生物科技公司 | 用于眼科用途的表面药物递送系统 |
| US8952051B2 (en) * | 2009-11-05 | 2015-02-10 | Allergan, Inc. | Ophthalmic formulations containing substituted gamma lactams and methods for use thereof |
| US20110136872A1 (en) * | 2009-12-09 | 2011-06-09 | Burk Robert M | Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof |
| US10272040B2 (en) | 2010-08-12 | 2019-04-30 | Nanyang Technological University | Liposomal formulation for ocular drug delivery |
| DE102011108948A1 (de) * | 2011-07-29 | 2013-01-31 | Achim Göpferich | Wässrige, kolloidale Lösungen von lipophilen Substanzen,insbesondere Arzneistofflösungen |
| EP2567689A1 (en) * | 2011-09-12 | 2013-03-13 | Visiotact Pharma | Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid |
| US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
| ES2669446B1 (es) * | 2016-11-24 | 2019-03-13 | Saiz Manuel Munoz | Producto oftálmico |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| GR1009419B (el) * | 2017-11-07 | 2018-12-14 | Φαρματεν Αβεε | Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου |
| AU2020217732A1 (en) * | 2019-02-06 | 2021-09-30 | TearClear Corp. | Systems and methods for preservative removal from ophthalmic formulations comprising complexing agents |
| US10993944B2 (en) | 2019-08-07 | 2021-05-04 | Aneira Pharma, Inc. | Methods and compositions for the treatment of hair loss |
| EP4167965A1 (en) * | 2020-06-21 | 2023-04-26 | i.com Medical GmbH | Use of high molecular weight hyaluronic acid as ocular transporting vehicle |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU665287B2 (en) * | 1992-12-21 | 1995-12-21 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
| US5631287A (en) | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
| US6646001B2 (en) | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| WO2000038689A1 (fr) | 1998-12-25 | 2000-07-06 | Sucampo, A.G. | Compositions de medicament pour traiter l'hypertension oculaire ou le glaucome |
| JP2003531824A (ja) | 2000-02-01 | 2003-10-28 | ケイマン ケミカル カムパニー，インク． | フルプロステノールおよび関連プロスタグランジンＦ２α類似体の内部１，１５−ラクトン、ならびに緑内障および眼高血圧の治療におけるそれらの使用 |
| US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| AR031135A1 (es) * | 2000-10-10 | 2003-09-10 | Upjohn Co | Composiciones de antibiotico topico para el tratamiento de infecciones oculares |
| AR035541A1 (es) * | 2000-11-13 | 2004-06-16 | Pharmacia Ab | Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio |
-
2004
- 2004-05-26 EP EP04748557A patent/EP1759702B1/en not_active Expired - Lifetime
- 2004-05-26 DE DE602004018990T patent/DE602004018990D1/de not_active Expired - Lifetime
- 2004-05-26 PL PL04748557T patent/PL1759702T3/pl unknown
- 2004-05-26 DK DK04748557T patent/DK1759702T3/da active
- 2004-05-26 ES ES04748557T patent/ES2320770T3/es not_active Expired - Lifetime
- 2004-05-26 SI SI200431084T patent/SI1759702T1/sl unknown
- 2004-05-26 AT AT04748557T patent/ATE419854T1/de active
- 2004-05-26 BR BRPI0418866-7A patent/BRPI0418866A/pt not_active IP Right Cessation
- 2004-05-26 US US11/597,459 patent/US8293789B2/en active Active
- 2004-05-26 WO PCT/MX2004/000034 patent/WO2005115401A1/es active Application Filing
- 2004-05-26 PT PT04748557T patent/PT1759702E/pt unknown
-
2005
- 2005-05-24 AR ARP050102140A patent/AR049113A1/es not_active Application Discontinuation
-
2011
- 2011-01-03 US US12/983,736 patent/US20110105605A1/en not_active Abandoned
- 2011-01-03 US US12/983,721 patent/US20110098354A1/en not_active Abandoned
- 2011-01-03 US US12/983,751 patent/US20110098355A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2320770T3 (es) | 2009-05-28 |
| EP1759702A1 (en) | 2007-03-07 |
| SI1759702T1 (sl) | 2009-06-30 |
| US20080021101A1 (en) | 2008-01-24 |
| US8293789B2 (en) | 2012-10-23 |
| DE602004018990D1 (de) | 2009-02-26 |
| PT1759702E (pt) | 2009-04-13 |
| US20110098354A1 (en) | 2011-04-28 |
| PL1759702T3 (pl) | 2009-06-30 |
| BRPI0418866A (pt) | 2007-11-20 |
| ATE419854T1 (de) | 2009-01-15 |
| US20110098355A1 (en) | 2011-04-28 |
| WO2005115401A1 (es) | 2005-12-08 |
| EP1759702B1 (en) | 2009-01-07 |
| DK1759702T3 (da) | 2009-04-20 |
| US20110105605A1 (en) | 2011-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049113A1 (es) | Un metodo para preparar una solucion oftalmica y solucion oftalmica obtenida de un agente activo como latanoprost | |
| NZ597626A (en) | Bicyclic compound and use thereof for medical purposes | |
| ES2461617T3 (es) | Composiciones farmacéuticas acuosas que contienen complejos borato-polioles | |
| ES2443548T3 (es) | Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol | |
| CO2019004776A2 (es) | Nuevos derivados de quinolina-3-carboxamida antihelmínticos | |
| ECSP12012037A (es) | Composiciones oftálmicas no irritantes de iodopovidona | |
| MX2009011391A (es) | Emulsion oftalmica aceite en agua que contiene prostaglandinas. | |
| MX2015002239A (es) | Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares. | |
| EA201190219A1 (ru) | Способы и композиции для лечения ишемических состояний и состояний, связанных с функцией митохондрий | |
| BR112014025711A2 (pt) | composto, medicamento, e, uso de um composto | |
| AR049979A1 (es) | Composicion oftalmica util para la colocacion intraocular en un ojo de un ser humano o animal y uso de un componente corticosteroide, un componente polimerico biocompatible y un componente solvente oftalmicamente compatible en una cantidad efectiva para solubilizar el componente polimerico para prep | |
| ATE428401T1 (de) | Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten | |
| CL2020002252A1 (es) | Formulación oftálmica. | |
| WO2011049713A3 (en) | Stabilized glucagon solutions | |
| DOP2015000169A (es) | Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas | |
| JP2013525493A5 (es) | ||
| PE20151066A1 (es) | Dispersion solida con solubilidad mejorada que comprende un derivado de tetrazol como ingrediente activo | |
| JP2013534527A5 (es) | ||
| UY28702A1 (es) | Derivados de quinazolina | |
| EA201691490A1 (ru) | Фармацевтическая композиция, содержащая бринзоламид | |
| MX2020006309A (es) | Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis. | |
| UY32829A (es) | Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo | |
| RU2014133697A (ru) | Композиция глазных капель | |
| WO2017152129A3 (en) | Treatment of glaucoma and/or retinal diseases and formulations useful therefore | |
| MXJL06000001A (es) | Metodo para preparar una solucion acuosa de meloxicam y solucion acuosa resultante. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |